Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (111-120 of 254) with videos related to

Pageof 26
Sort By:
Cell Host & Microbe|March 4, 2022
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2Hongjie Xia, Jing Zou, Chaitanya Kurhade, et al.
Human Vaccines & Immunotherapeutics|November 11, 2022
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal diseaseCharu Sabharwal, Vani Sundaraiyer, Yahong Peng, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 28, 2020
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeDonald Hurley, Carl Griffin, Mariano Young, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B DiseaseGary W Zlotnick, Thomas R Jones, Paul Liberator, et al.
Virology|March 7, 2002
Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV typesN D Christensen, N M Cladel, C A Reed, et al.
Nature Communications|June 23, 2022
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccineChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyDorothee M Kieninger, Kathrin Kueper, Katrin Steul, et al.
Vaccine|March 11, 2014
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of ageRichard N Greenberg, Alejandra Gurtman, Robert W Frenck, et al.
Pageof 26

Showing results (111-120 of 254) with videos related to

Sort By:
Pageof 26
Cell Host & Microbe|March 4, 2022
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2Hongjie Xia, Jing Zou, Chaitanya Kurhade, et al.
Human Vaccines & Immunotherapeutics|November 11, 2022
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal diseaseCharu Sabharwal, Vani Sundaraiyer, Yahong Peng, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 28, 2020
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeDonald Hurley, Carl Griffin, Mariano Young, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B DiseaseGary W Zlotnick, Thomas R Jones, Paul Liberator, et al.
Virology|March 7, 2002
Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV typesN D Christensen, N M Cladel, C A Reed, et al.
Nature Communications|June 23, 2022
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccineChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyDorothee M Kieninger, Kathrin Kueper, Katrin Steul, et al.
Vaccine|March 11, 2014
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of ageRichard N Greenberg, Alejandra Gurtman, Robert W Frenck, et al.
Pageof 26